Current Partnering’s pick of the latest and largest financing announcements…
ConforMIS reaches funding milestone with $89 million in series E financing
February 1, 2012 : financings
ConforMIS announced that it has raised $89 million in a Series E round of funding, with additional funds beyond this amount committed upon meeting certain milestones. more »
Why Biogen Idec Got Out of the Corporate VC Business
January 30, 2012 : Big Pharma, Biogen Idec, financings, venture capital
Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French more »
Verastem announces pricing of initial public offering
January 27, 2012 : financings
Verastem announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.
All of the shares in the offering are being sold by Verastem. more »
ProSensa raises €23 million in equity sale
January 25, 2012 : financings
Prosensa has raised €23 million in new equity financing.
The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. more »
Leading private venture capital firms invest $45 million in Mevion Medical Systems
January 24, 2012 : financings
Mevion Medical Systems has closed a $45 Million investment from ProQuest Investments and its existing investors, including Caxton Heath Life Sciences, Venrock and CHL Medical Partners. more »
Westphal’s Verastem plans $45 million IPO next week
January 24, 2012 : dealtalk, financings
Verastem, a one-year old startup focused on developing drugs that target cancer stem cells, plans to set pricing for its IPO during the week of Jan. 23, the IPO research firm Renaissance Capital reported, Friday. more »
RBCC vets investment banks for capital raise
January 23, 2012 : dealtalk, financings
Rainbow Coral Corp. begins the search today for a capable investment banking firm to assist in procuring capital for the acquisition of Nano3D Biosciences (n3D) and other target companies. 
more »
Neurocrine prices public offering of common stock
January 20, 2012 : financings
Neurocrine Biosciences announced the pricing of an underwritten public offering of 9,500,000 shares of its common stock at a price to the public of $8.10 per share. more »
Prestige Brands announces offering of $290 million senior notes
January 19, 2012 : financings
Prestige Brands intends to offer, subject to market and other conditions, up to $290 million in aggregate principal amount of new senior notes due 2020 (the “Notes”) in a private offering. The Notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries. more »
Sequenom prices public offering of common stock
January 19, 2012 : financings
Sequenom announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock, offered at a price to the public of $4.15 per share. more »
